BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  C2C Services & Suppliers™
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
Get Our Industry eNewsletter FREE email:    
   

InVitria Release: Recent Study Reveals Animal-Free Expansion Media Components Eliminate Need for Blood Products in Mononuclear and Hematopoietic Stem Cells


3/1/2011 11:33:29 AM

Fort Collins, CO, USA, March 1, 2011 / b3c newswire / – A recent study demonstrated that Cellastim® (recombinant human albumin) and Optiferrin® (recombinant human transferrin) deliver superior xeno-free and animal-free solutions for primary cell and stem cell expansion media. The study revealed that the combination of Cellastim and Optiferrin delivered a 250-300% increase in performance over the best animal-derived combination. These research findings were presented at the Stem Cells & Regenerative Medicine World Congress, January 2011 poster session.

Improving the expansion of primary cells and stems cells is a major challenge in regenerative medicine. The majority of serum-free stem cell expansion media contain undesirable animal-derived components such as plasma-derived human albumin (for nutritional support) or human transferrin (for efficient iron delivery). If these components are human blood-derived they qualify as xeno-free, however they remain a concern due to transmission risk inherent in blood products. “Blood-derived proteins can be variable from batch-to-batch leading to inconsistencies in media performance,” stated Dr. Steve Pettit, Director of Cell Culture Development at InVitria. “This study showed that Cellastim and Optiferrin allowed the cells to remain undifferentiated and continued cell growth in stem cell expansion media; another demonstration that they are superior replacements for blood-derived proteins.”

The data shows that Cellastim and Optiferrin are robust components that enable the development of superior xeno-free and blood product-free expansion media.

Dr. Pettit will share the data from this study as well as other studies in stem and primary cells during an upcoming webinar on March 1st, 2011, titled, Maximizing Performance: Solutions for Stem Cells and Regenerative Medicines. All webinar registrants will receive a copy of the stem cell poster presented at the Stem Cells & Regenerative Medicine World Congress. Click here to register today.

About InVitria - www.invitria.com

InVitria develops, manufactures and markets a portfolio of products used in cell culture, diagnostics and bioproduction. InVitria’s products address customer needs for defined, xeno-free, blood product-free and animal component-free cell culture supplements in stem cell technology, regenerative medicine, biomanufacturing, diagnostics, biopharmaceutical formulation, cell-based vaccines and general life science research.

To obtain more information about InVitria’s product solutions, e-mail info@InVitria.com or call 1-800-916-8311.


Read at BioSpace.com

InVitria
 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES
 

//-->